Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges
by
Melcher, Alan
, Vile, Richard
, Ungerechts, Guy
, Chiocca, E Antonio
, Appleton, Elizabeth
in
Antibodies
/ Antigens
/ Antineoplastic drugs
/ Cancer
/ Cancer therapies
/ Cell death
/ Clinical trials
/ FDA approval
/ Herpes viruses
/ Humans
/ Immune response
/ Immunity (Disease)
/ Immunology
/ Immunotherapy
/ Immunotherapy - methods
/ Lymphocytes
/ Medical research
/ Melanoma
/ Neoplasms - immunology
/ Neoplasms - therapy
/ Oncolysis
/ Oncolytic Virotherapy - methods
/ Oncolytic Virotherapy - trends
/ Oncolytic Viruses
/ Patients
/ Tumor Microenvironment
/ Tumors
/ Viral infections
/ Virulence
/ Viruses
2025
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges
by
Melcher, Alan
, Vile, Richard
, Ungerechts, Guy
, Chiocca, E Antonio
, Appleton, Elizabeth
in
Antibodies
/ Antigens
/ Antineoplastic drugs
/ Cancer
/ Cancer therapies
/ Cell death
/ Clinical trials
/ FDA approval
/ Herpes viruses
/ Humans
/ Immune response
/ Immunity (Disease)
/ Immunology
/ Immunotherapy
/ Immunotherapy - methods
/ Lymphocytes
/ Medical research
/ Melanoma
/ Neoplasms - immunology
/ Neoplasms - therapy
/ Oncolysis
/ Oncolytic Virotherapy - methods
/ Oncolytic Virotherapy - trends
/ Oncolytic Viruses
/ Patients
/ Tumor Microenvironment
/ Tumors
/ Viral infections
/ Virulence
/ Viruses
2025
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges
by
Melcher, Alan
, Vile, Richard
, Ungerechts, Guy
, Chiocca, E Antonio
, Appleton, Elizabeth
in
Antibodies
/ Antigens
/ Antineoplastic drugs
/ Cancer
/ Cancer therapies
/ Cell death
/ Clinical trials
/ FDA approval
/ Herpes viruses
/ Humans
/ Immune response
/ Immunity (Disease)
/ Immunology
/ Immunotherapy
/ Immunotherapy - methods
/ Lymphocytes
/ Medical research
/ Melanoma
/ Neoplasms - immunology
/ Neoplasms - therapy
/ Oncolysis
/ Oncolytic Virotherapy - methods
/ Oncolytic Virotherapy - trends
/ Oncolytic Viruses
/ Patients
/ Tumor Microenvironment
/ Tumors
/ Viral infections
/ Virulence
/ Viruses
2025
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges
Journal Article
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges
2025
Request Book From Autostore
and Choose the Collection Method
Overview
Immunotherapy has transformed the treatment of cancer, yet many patients do not have response or lasting benefit. Strategies to overcome resistance remain of crucial importance. Oncolytic viruses offer a promising approach, with the unique ability to selectively replicate within (and to destroy) cancer cells, remodel the immunosuppressive tumour microenvironment, and stimulate antitumour immunity. Interest in the potential of oncolytic viruses has grown steadily over the past two decades, fuelled by advances in cancer immunology and viral engineering. However, clinical translation has not kept pace, and although a plethora of promising new constructs have entered clinical testing, several barriers continue to restrict widespread clinical implementation. This Therapeutics paper highlights key milestones in oncolytic virus clinical development, discusses the challenges that remain, and, through clinical reflection, considers how future research might be streamlined to achieve meaningful benefit for patients.
Publisher
Elsevier Limited
Subject
MBRLCatalogueRelatedBooks
Related Items
Related Items
This website uses cookies to ensure you get the best experience on our website.